← All trials
NCT05974579
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2023
- Primary completion
- May 31, 2024
- Completion date
- Jul 31, 2024
- First posted
- Aug 3, 2023
- Last posted
- Nov 29, 2023
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of SherbrookeLead sponsor
- Eli LillyCollaborator
- University of SherbrookeOverall official - principal investigator
- University of SherbrookeStudy director
- University of SherbrookeOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.